A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity

This study is a multicenter, randomized, double‐blind, placebo‐controlled phase II studyconducted in China. It aims to evaluate the efficacy and safety of MWN109 injection innon‐diabetic participants with overweight or obesity.A total of 120 participants were enrolled in the study. All participants were randomlyassigned using stratified block randomization by gender (male or female) and allocated to4 treatment groups at a 1:1:1:1 ratio, with approximately 30 participants in each group.Each treatment group will reach the This study consists of a screening period of up to 2weeks, a treatment period of 24 weeks, and a follow‐up period of 2 weeks, totaling 28weeks. The primary endpoint is the percentage change in body weight compared to thebaseline after 24 weeks of drug administration. The secondary endpoints include theproportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20%relative to the baseline after 24 weeks of treatment, as well as the change in waistcircumference relative to the baseline.target dose through dose titration.